155 related articles for article (PubMed ID: 35482932)
1. Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.
Jiang W; Sha M; Chen C
Am J Ther; 2023 Nov-Dec 01; 30(6):e570-e572. PubMed ID: 35482932
[No Abstract] [Full Text] [Related]
2. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
3. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
4. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
5. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
Wei Q; Zhang J; Chen D; Li S; Liu Y
Lung Cancer; 2020 Oct; 148():175-176. PubMed ID: 32883519
[No Abstract] [Full Text] [Related]
6. A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
Liang P; Qi L; Guo T; You X; Cui C
Lung Cancer; 2021 Feb; 152():193-195. PubMed ID: 33388164
[No Abstract] [Full Text] [Related]
7. A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.
Oyamada Y; Wada S; Fujimoto K
Gan To Kagaku Ryoho; 2021 Jun; 48(6):845-847. PubMed ID: 34139737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
9. Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.
Liu Y; Wu Y; Wu F; Hu C
Chemotherapy; 2022; 67(4):248-252. PubMed ID: 35764055
[TBL] [Abstract][Full Text] [Related]
10. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
[TBL] [Abstract][Full Text] [Related]
11. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
[No Abstract] [Full Text] [Related]
12. A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.
Zhuang W; Zhong J; Wang J
Lung Cancer; 2023 Apr; 178():131-133. PubMed ID: 36842378
[No Abstract] [Full Text] [Related]
13. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
Zaemes J; Hall RD; Gentzler RD
J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
[No Abstract] [Full Text] [Related]
14. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
Fang W; Huang Y; Gan J; Shao YW; Zhang L
J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
[No Abstract] [Full Text] [Related]
15. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
Wang XF; Zhao QT; Chen C
Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
[No Abstract] [Full Text] [Related]
16. A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.
Kimura H; Amino Y; Koba H; Tambo Y; Ohkura N; Hara J; Sone T; Kasahara K
Cancer Commun (Lond); 2019 Nov; 39(1):67. PubMed ID: 31675980
[No Abstract] [Full Text] [Related]
17. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
18. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report.
Huang J; Wang Y; Zhai Y; Wang J
Thorac Cancer; 2018 Jun; 9(6):745-749. PubMed ID: 29673089
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
